Last updated: September 9, 2026
Technetium Tc-99m tilmanocept, marketed as Lymphoseek, is a specialized radiopharmaceutical used for lymphatic mapping and sentinel lymph-node detection. Its commercial position depends more on hospital adoption, nuclear-pharmacy distribution, procedure volumes, reimbursement, and manufacturing reliability than on broad prescription-market expansion. Navidea Biopharmaceuticals remains the product’s principal commercial beneficiary, while Cardinal Health has supplied or distributed the product through nuclear-pharmacy channels.
Lymphoseek has a defensible but narrow market position. It offers targeted binding to mannose receptors on macrophages and improved lymph-node targeting relative to older mapping agents. Its main commercial constraints are the short half-life of technetium-99m, procedure-specific utilization, hospital purchasing budgets, competing mapping agents, and a concentrated customer base.
What is technetium Tc-99m tilmanocept used for?
Technetium Tc-99m tilmanocept is an injectable radiolabeled diagnostic agent used to identify lymph nodes that drain a primary tumor. The product is prepared from a kit and administered after radiolabeling with technetium-99m.
The FDA-approved uses include:
- Lymphatic mapping performed with a handheld gamma detection device.
- Sentinel lymph-node detection in patients with breast cancer or melanoma.
- Sentinel lymph-node detection in patients with head and neck cancer.
The product is not a systemic cancer treatment. Its value is procedural: it supports surgical staging and localization of tumor-draining lymph nodes.
The mechanism combines a dextran backbone with mannose groups that bind CD206 receptors on macrophages. The technetium-99m label permits external gamma detection during imaging and surgery. The product’s targeting characteristics can support identification of sentinel nodes that may be difficult to identify with less specific mapping agents.
How large is the technetium Tc-99m tilmanocept market?
The addressable market is a niche segment of the broader nuclear-medicine and sentinel-node mapping market. Demand is linked to:
- Breast-cancer surgery and sentinel-node biopsy.
- Melanoma staging.
- Head and neck oncology procedures.
- Hospital adoption of targeted lymphatic mapping.
- Availability of technetium-99m and nuclear-pharmacy preparation capacity.
Lymphoseek competes with established low-cost alternatives, including technetium-labeled sulfur colloid, filtered sulfur colloid, isosulfan blue, methylene blue, indocyanine green, and combinations of radioactive and visual dyes. In some hospitals, Lymphoseek is used selectively for cases in which its targeting, imaging performance, or workflow benefits justify a higher acquisition cost.
The market is therefore characterized by moderate clinical differentiation but limited pricing power. A product can gain share without expanding the total number of sentinel-node procedures.
What factors drive adoption?
| Market factor |
Effect on Lymphoseek |
| Breast-cancer procedure volume |
Supports recurring demand |
| Head and neck cancer use |
Expands utilization but remains smaller than breast cancer |
| Nuclear-pharmacy access |
Determines whether hospitals can use the product reliably |
| Reimbursement |
Controls hospital willingness to absorb product cost |
| Technetium-99m supply |
Creates operational risk |
| Surgeon preference |
Influences repeat use and formulary retention |
| Competing dyes and colloids |
Limits pricing and market expansion |
| Product wastage |
Short radiopharmaceutical shelf life can affect economics |
Lymphoseek’s commercial model differs from ordinary pharmaceuticals. Inventory cannot be held for long periods, and doses must be coordinated with surgery schedules. This favors companies with established nuclear-pharmacy networks and regional distribution infrastructure.
What is the financial trajectory for Lymphoseek?
Navidea’s disclosed product revenue has shown recovery and growth after the COVID-19 disruption to elective surgery. Public filings describe Lymphoseek as the company’s principal commercial product and primary revenue source.
A representative trajectory based on Navidea’s annual reporting is:
| Period |
Commercial trend |
| 2019 |
Established recurring product revenue before the pandemic |
| 2020 |
Decline caused by reduced elective surgeries and hospital disruption |
| 2021 |
Recovery as surgical volumes resumed |
| 2022 |
Continued growth in product sales and procedure utilization |
| 2023 |
Further expansion, supported by commercial execution and higher procedure volumes |
Public disclosures have placed annual Lymphoseek-related product revenue in the tens of millions of dollars rather than the hundreds of millions typical of large specialty pharmaceuticals. The company’s revenue base remains concentrated, which creates operating leverage but also significant dependence on one commercial asset.
The financial profile has four important characteristics:
- Revenue is recurring but concentrated.
- Gross economics are affected by radiopharmaceutical manufacturing and distribution costs.
- Growth depends on procedure volume and market penetration rather than chronic treatment duration.
- Cash generation is vulnerable to litigation, debt obligations, commercialization expenses, and supply interruptions.
Navidea’s financial trajectory should therefore be evaluated as a single-product specialty-pharmaceutical business. Lymphoseek revenue growth does not automatically translate into equivalent earnings growth because the company must support manufacturing, regulatory compliance, commercial distribution, and corporate obligations.
Which companies commercialize technetium Tc-99m tilmanocept?
Navidea Biopharmaceuticals developed Lymphoseek and has been the principal rights holder associated with the product. Cardinal Health has played a major role in distribution and nuclear-pharmacy commercialization.
The commercial structure gives Cardinal Health strategic importance even where Navidea retains economic rights. Cardinal’s nuclear-pharmacy network can provide:
- Regional dose preparation.
- Hospital account coverage.
- Radiopharmaceutical logistics.
- Integration with existing nuclear-medicine purchasing.
- Operational support for short-lived radioactive products.
The arrangement also creates counterparty concentration. If a distribution or supply agreement changes, Navidea’s commercial economics, working capital requirements, and market access could change materially.
What patents protect technetium Tc-99m tilmanocept?
The patent estate has historically focused on tilmanocept’s composition, mannosylated dextran structures, radiolabeling, and use in lymphatic mapping. The commercial protection is narrower than the protection typically available for a new small-molecule therapeutic because generic or competing products may avoid the exact claimed composition while pursuing the same clinical procedure.
Key protection categories include:
| Protection category |
Commercial relevance |
| Tilmanocept composition claims |
Protect the core targeted macromolecule |
| Mannosylated dextran chemistry |
Protects the receptor-binding structure |
| Radiolabeled formulations |
Covers the prepared diagnostic product |
| Lymphatic mapping methods |
Supports use-based enforcement |
| Kit and preparation claims |
Can address commercial manufacturing and administration |
| Manufacturing processes |
May create practical barriers even after composition expiry |
Public patent records associated with tilmanocept include patents covering mannosylated dextran derivatives and related diagnostic applications. Patent terms vary by family, jurisdiction, patent-term adjustment, terminal disclaimers, and maintenance status. The relevant U.S. protection has generally been understood to extend into the late 2020s for at least some patent families, although the commercial blocking position must be confirmed patent by patent.
Patent expiry does not necessarily produce immediate generic entry. A competing sponsor would still need to:
- Develop a radiolabeled kit.
- Demonstrate pharmaceutical quality and radiation-handling controls.
- Establish technetium-labeling performance.
- Conduct FDA-required studies.
- Secure nuclear-pharmacy manufacturing capacity.
- Obtain hospital formulary adoption.
- Meet reimbursement and supply-chain requirements.
What is the Orange Book status of Lymphoseek?
Lymphoseek was approved under FDA NDA 204630. The FDA Orange Book is the primary source for identifying patents listed against an approved drug product and for determining whether a generic applicant may file a Paragraph IV certification.
For Lymphoseek, Orange Book analysis should distinguish between:
- Patents listed against the NDA.
- Patents covering tilmanocept but not listed in the Orange Book.
- Patent applications or unexpired claims that are not enforceable against every competing product.
- Regulatory exclusivity, which is separate from patent protection.
A listed patent may delay approval of an abbreviated new drug application after a Paragraph IV notice. An unlisted patent can still support patent litigation, but it does not automatically trigger the same FDA approval stay.
Because Lymphoseek is a radiolabeled kit product with complex formulation and preparation requirements, Orange Book listings are only one part of the entry analysis. A competitor may face commercial and technical barriers even if no listed patent blocks filing.
When does Lymphoseek lose exclusivity?
Lymphoseek’s exclusivity is layered rather than tied to one single date.
| Exclusivity layer |
Status and implication |
| FDA approval |
Product approved in 2013, with later expansion to head and neck cancer |
| Regulatory exclusivity |
Early approval-related exclusivity has expired |
| Composition patents |
Some protection may extend into the late 2020s |
| Use patents |
Scope depends on the indication and claim language |
| Formulation and kit patents |
Could affect product-specific entry |
| Trade secrets and know-how |
May remain relevant after patent expiry |
| Nuclear-pharmacy infrastructure |
Creates practical, nonstatutory barriers |
The earliest commercially relevant loss of exclusivity is not necessarily the earliest patent expiration date. Generic entry may require a product that reproduces the radiolabeling, stability, dosage, kit configuration, and clinical performance of Lymphoseek. A competitor that uses a different molecule or mapping technology may avoid tilmanocept patents but compete clinically.
Are there Paragraph IV challenges to Lymphoseek?
A Paragraph IV challenge requires an ANDA applicant to certify that a listed patent is invalid, unenforceable, or not infringed. Publicly visible litigation and regulatory records should be reviewed for any current ANDA challenge, but Lymphoseek has not developed the high-volume Paragraph IV litigation profile associated with blockbuster oral medicines.
The reasons include:
- Small commercial revenue relative to development cost.
- Specialized radioactive manufacturing requirements.
- Limited number of potential generic manufacturers.
- Need for nuclear-pharmacy distribution.
- Competition from non-generic sentinel-node mapping agents.
- Uncertain return on investment from a narrowly focused product.
The absence of a prominent Paragraph IV event does not eliminate generic risk. A rival could pursue a 505(b)(2) pathway, develop a distinct radiolabeled mapping product, or enter after relevant patents expire.
How strong is the patent estate for technetium Tc-99m tilmanocept?
The patent estate is commercially meaningful but not impenetrable.
Its strengths are:
- Protection around a specialized receptor-targeted composition.
- Potential coverage of kit-based radiolabeling and use.
- Technical complexity that may discourage casual entry.
- Limited availability of direct substitutes with identical molecular targeting.
Its weaknesses are:
- Narrow clinical market.
- Potential design-around opportunities.
- Dependence on claim construction and patent validity.
- Expiring composition and method claims.
- Availability of alternative mapping agents that do not need to copy tilmanocept.
The estate is stronger as a barrier to direct tilmanocept copies than as a barrier to broader competition in sentinel-node mapping.
What litigation and settlement risks affect Lymphoseek?
The principal legal risks are likely to involve:
- Patent validity and infringement.
- Distribution and supply agreements.
- Manufacturing quality.
- Royalty or revenue-sharing obligations.
- Contract rights between Navidea and commercial partners.
- Product liability associated with diagnostic use.
A settlement with a generic challenger, if reached, could establish a negotiated launch date before patent expiry. No commercially material settlement date should be assumed without a filed agreement, court order, or company disclosure.
For investors and licensing counterparties, the most important litigation questions are whether a challenger has filed an ANDA, whether a 30-month stay has been triggered, whether the product’s core patent claims remain valid, and whether any settlement restricts the launch of an alternative mapping agent.
What manufacturing and intellectual-property barriers exist?
Lymphoseek requires more than conventional drug-tablet manufacturing. The commercial product depends on:
- Production of the tilmanocept kit.
- Controlled radiolabeling with technetium-99m.
- Validated sterility and quality systems.
- Short-interval distribution.
- Nuclear-pharmacy handling.
- Dose scheduling with hospitals.
- Reliable access to technetium generators or centralized supply.
These requirements create operational barriers that can protect incumbent revenue after formal patent expiry. They also create supply risk. A batch failure, generator shortage, transportation delay, or nuclear-pharmacy disruption can directly reduce billable procedures.
How does Lymphoseek compare with competing mapping agents?
| Product or technology |
Main advantage |
Main limitation |
| Lymphoseek |
Targeted macrophage binding and lymphatic mapping |
Higher complexity and cost |
| Technetium sulfur colloid |
Familiar, relatively low-cost radioactive mapping |
Less targeted biological mechanism |
| Isosulfan blue |
Visual confirmation of lymphatic channels |
Allergy risk and lower standalone localization utility |
| Methylene blue |
Low cost and visual mapping |
Tissue staining and safety limitations |
| Indocyanine green |
Near-infrared visualization |
Requires compatible imaging equipment |
| Combined radioactive and dye methods |
Multiple detection modalities |
Higher procedural complexity and cost |
Lymphoseek is most competitive where surgeons and nuclear-medicine teams value targeted node localization, reproducibility, or workflow benefits. It is less advantaged where hospitals prioritize lowest acquisition cost or already have a stable sulfur-colloid protocol.
What generic launch scenarios exist?
Early alternative entry
A competitor could pursue a 505(b)(2) application for a different formulation or radiolabeled mapping product. This would create competitive pressure without requiring a direct ANDA copy.
Patent-challenge entry
An ANDA applicant could challenge listed patents through Paragraph IV certifications. Litigation would determine whether launch could occur before the relevant patent expirations.
Post-expiry direct generic entry
After core patents expire, a generic or authorized alternative could enter if it can reproduce kit performance, manufacturing quality, and distribution economics.
Non-generic clinical substitution
Hospitals may switch to sulfur colloid, dyes, or fluorescence-based mapping without waiting for Lymphoseek patents to expire. This is the most immediate form of competitive risk because it does not require a direct copy.
What is the revenue exposure for Navidea and commercial partners?
Navidea’s exposure is unusually concentrated because Lymphoseek is its principal commercial asset. Revenue risk is tied to:
- Breast and melanoma surgical volumes.
- Head and neck procedure growth.
- Hospital formulary decisions.
- Cardinal Health distribution performance.
- Product pricing and reimbursement.
- Supply continuity.
- Patent and regulatory developments.
For Cardinal Health, Lymphoseek is more likely to be a niche product within a broad nuclear-pharmacy portfolio. For Navidea, the same product has substantially greater financial significance. This difference affects negotiating leverage, partnership economics, and the impact of any supply or litigation event.
Key Takeaways
- Technetium Tc-99m tilmanocept, sold as Lymphoseek, is a targeted diagnostic radiopharmaceutical for sentinel lymph-node mapping.
- Its market is specialized, procedure-driven, and dependent on nuclear-pharmacy infrastructure.
- Revenue recovered after the pandemic disruption to elective surgery and has remained concentrated in one commercial product.
- Navidea has high financial exposure to Lymphoseek, while Cardinal Health provides important distribution and nuclear-pharmacy capabilities.
- Patent protection covers tilmanocept composition, formulation, kit, manufacturing, and use claims, with relevant U.S. protection extending into the late 2020s for some patent families.
- Direct generic entry is constrained by the small market, radioactive manufacturing requirements, and distribution complexity.
- The larger near-term risk is clinical substitution by sulfur colloid, dyes, fluorescence imaging, or other lymphatic-mapping technologies.
- Orange Book patents, patent litigation, supply agreements, and FDA pathway selection should be analyzed together rather than separately.
FAQs
Is Lymphoseek a radioactive cancer treatment?
No. Lymphoseek is a diagnostic radiopharmaceutical used to locate lymph nodes during cancer staging and surgery. It does not treat the underlying cancer.
Does Lymphoseek require technetium-99m availability?
Yes. The kit must be radiolabeled with technetium-99m before administration. Generator supply, radiopharmacy capacity, and scheduling are central to commercial use.
Can a generic company copy Lymphoseek after patent expiry?
A generic company could pursue entry, but it would still need to meet FDA requirements for the kit, radiolabeling process, sterility, stability, manufacturing, and distribution. Patent expiry does not guarantee immediate commercial substitution.
Is Lymphoseek protected by orphan-drug exclusivity?
Lymphoseek’s principal commercial protection has been based on FDA approval, patents, formulation know-how, and distribution infrastructure rather than a broad orphan-drug exclusivity strategy.
What is the main investment risk associated with Lymphoseek?
The main risk is product concentration. Navidea’s financial performance depends heavily on a single niche radiopharmaceutical whose demand is linked to surgical volume, hospital purchasing, reimbursement, supply reliability, and competition from alternative mapping technologies.
References
-
Cardinal Health. (2023). Annual report for fiscal year 2023. Cardinal Health, Inc.
-
Food and Drug Administration. (2013). Lymphoseek: Prescribing information and approval history. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Navidea Biopharmaceuticals, Inc. (2023). Annual report and Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for tilmanocept and mannosylated dextran compositions. U.S. Department of Commerce.
